Alumis Inc.: shareholders and insiders

ALMSNASDAQHealthcare · Pharmaceutical Preparations

Price

$4.33

November 19, 2026Market cap $560M

What Ploutos Investor adds for Alumis

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history in every section
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 28% since Nov 12, 2026, when the 10-Q these figures come from was filed ($6.13 then, $4.40 on Nov 18, 2026). The figures date from before that move.10-Q

Insiders and their shares

Purchases and sales by officers and directors, from their own Form 4 filings.

Reading the newest filings from the SEC. This part fills in on its own in a few seconds.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

5 Holders over 5%3 On a 13DNov 5, 2026 Latest filing
  • Foresite Capital Fund VI LPwith 11 more persons
    Share of class12.7%
  • AyurMaya Capital Management Company, LPwith 1 more person
    Share of class12.3%
  • Deep Track Capital, LPwith 2 more persons
    Share of class5.98%
  • BlackRock, Inc.
    Share of class5.70%
  • Samsara BioCapital, L.P.with 4 more persons
    Share of class5.40%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Foresite Capital Fund VI LP12.7%From the filing of Apr 3, 2026

    The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock; general market and…

    From the filing of Apr 3, 2026
  • AyurMaya Capital Management Company, LP12.3%From the filing of May 23, 2025

    The Merger closed on May 21, 2025. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock of ACELYRIN, par value $0.00001 per share (collectively, the "ACELYRIN Shares"), was cancelled and converted into the right to receive 0.4814 shares of Common Stock of the Issuer, without interest and, if applicable, cash in lieu of fractional shares, without interest, subject to any applicable withholding. Accordingly, at the Effective Time of the Merger, the AyurMaya Fund received, in exchange for its 9,334,735 ACELRYIN Shares, approximately 4,493,741 shares of Common Stock, as disclosed to the Reporting Persons…

    From the filing of May 23, 2025
  • Samsara BioCapital, L.P.5.4%From the filing of Nov 24, 2025

    The Reporting Persons purchased the aforementioned securities for investment purposes with the aim of increasing the value of their investments and the Issuer. Subject to applicable legal requirements, one or more of the Reporting Persons may purchase additional securities of the Issuer from time to time in open market or private transactions, depending on its evaluation of the Issuer's business, prospects and financial condition, the market for the Issuer's securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons' ownership of the Issuer's securities, other opportunities available to the Reporting Persons, and general economic, money market…

    From the filing of Nov 24, 2025
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • FMR0.00%Nov 5, 202613G/A
  • venBio Global Strategic Fund IV, L.P.4.80%Nov 17, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Millennium Mgmt (Englander)
    In the quarter+405%
  • Citadel Advisors (Griffin)
    In the quarter
  • D.E. Shaw
    In the quarter-68%
  • Renaissance Technologies
    In the quarter
  • AQR Capital
    In the quarter+383%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 8.57% of its shares outstanding were held short, +7.6% since the report before.

Shares held short
11.08M
8.57%
Since the report before10.30M on Sep 30, 2026
+7.6%
4.9
2.28M
More days to cover thanof 4,578 US-listed companies with enough volume
59%
Report date
Oct 15, 2026
  • Jul 15, 2024: Shares held short 610.2K
  • Jul 31, 2024: Shares held short 680.2K
  • Aug 15, 2024: Shares held short 865.4K
  • Aug 30, 2024: Shares held short 1.28M
  • Sep 13, 2024: Shares held short 1.48M
  • Sep 30, 2024: Shares held short 2.14M
  • Oct 15, 2024: Shares held short 2.19M
  • Oct 31, 2024: Shares held short 2.17M
  • Nov 15, 2024: Shares held short 2.22M
  • Nov 29, 2024: Shares held short 2.43M
  • Dec 13, 2024: Shares held short 2.54M
  • Dec 31, 2024: Shares held short 2.40M
  • Jan 15, 2025: Shares held short 2.39M
  • Jan 31, 2025: Shares held short 2.37M
  • Feb 14, 2025: Shares held short 2.81M
  • Feb 28, 2025: Shares held short 2.94M
  • Mar 14, 2025: Shares held short 3.05M
  • Mar 31, 2025: Shares held short 4.09M
  • Apr 15, 2025: Shares held short 3.12M
  • Apr 30, 2025: Shares held short 3.53M
  • May 15, 2025: Shares held short 4.64M
  • May 30, 2025: Shares held short 3.69M
  • Jun 13, 2025: Shares held short 3.22M
  • Jun 30, 2025: Shares held short 4.03M
  • Jul 15, 2025: Shares held short 3.23M
  • Jul 31, 2025: Shares held short 2.89M
  • Aug 15, 2025: Shares held short 1.85M
  • Aug 29, 2025: Shares held short 2.04M
  • Sep 15, 2025: Shares held short 2.37M
  • Sep 30, 2025: Shares held short 2.85M
  • Oct 15, 2025: Shares held short 2.11M
  • Oct 31, 2025: Shares held short 2.81M
  • Nov 14, 2025: Shares held short 3.53M
  • Nov 28, 2025: Shares held short 3.53M
  • Dec 15, 2025: Shares held short 3.87M
  • Dec 31, 2025: Shares held short 4.49M
  • Jan 15, 2026: Shares held short 8.67M
  • Jan 30, 2026: Shares held short 8.67M
  • Feb 13, 2026: Shares held short 9.05M
  • Feb 27, 2026: Shares held short 7.95M
  • Mar 13, 2026: Shares held short 8.96M
  • Mar 31, 2026: Shares held short 11.23M
  • Apr 15, 2026: Shares held short 12.21M
  • Apr 30, 2026: Shares held short 11.29M
  • May 15, 2026: Shares held short 11.36M
  • May 29, 2026: Shares held short 11.07M
  • Jun 15, 2026: Shares held short 12.66M
  • Jun 30, 2026: Shares held short 14.29M
  • Jul 15, 2026: Shares held short 6.76M
  • Jul 31, 2026: Shares held short 5.77M
  • Aug 14, 2026: Shares held short 5.85M
  • Aug 31, 2026: Shares held short 5.65M
  • Sep 15, 2026: Shares held short 6.30M
  • Sep 30, 2026: Shares held short 10.30M
  • Oct 15, 2026: Shares held short 11.08M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading40.3% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 40.3% of the shares in the reported trades were short sales, against 34.7% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
40.3%
The 14 beforeOct 12, 2026 – Oct 29, 2026
34.7%
Change
+5.6 pts
Short sales a dayon average, of 672.2K shares
271.2K
More than atof 3,656 US-listed companies, same days
21%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 31.8%
  • Oct 13, 2026: Short sales 44%
  • Oct 14, 2026: Short sales 42.7%
  • Oct 15, 2026: Short sales 34%
  • Oct 16, 2026: Short sales 53.6%
  • Oct 19, 2026: Short sales 53.7%
  • Oct 20, 2026: Short sales 47.1%
  • Oct 21, 2026: Short sales 44.5%
  • Oct 22, 2026: Short sales 34.9%
  • Oct 23, 2026: Short sales 49.5%
  • Oct 26, 2026: Short sales 39.7%
  • Oct 27, 2026: Short sales 22.3%
  • Oct 28, 2026: Short sales 26.4%
  • Oct 29, 2026: Short sales 14.8%
  • Oct 30, 2026: Short sales 23.9%
  • Nov 2, 2026: Short sales 30.6%
  • Nov 3, 2026: Short sales 37.9%
  • Nov 4, 2026: Short sales 43.9%
  • Nov 5, 2026: Short sales 37.4%
  • Nov 6, 2026: Short sales 20.2%
  • Nov 9, 2026: Short sales 40%
  • Nov 10, 2026: Short sales 50.5%
  • Nov 11, 2026: Short sales 43.1%
  • Nov 12, 2026: Short sales 67.5%
  • Nov 13, 2026: Short sales 48.7%
  • Nov 16, 2026: Short sales 40.3%
  • Nov 17, 2026: Short sales 40.5%
  • Nov 18, 2026: Short sales 44.5%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

14 ETFs holding it0.55% The largest weight (IHE)
  • IHEiShares U.S. Pharmaceuticals ETF
    Weight in the fund0.55%
  • IBBiShares Biotechnology ETF
    Weight in the fund0.18%
  • FESMFidelity Enhanced Small Cap Core ETF
    Weight in the fund0.17%
  • IWOiShares Russell 2000 Growth ETF
    Weight in the fund0.12%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.07%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.06%
  • SCHASchwab U.S. Small-Cap ETF
    Weight in the fund0.04%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.03%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.02%
  • ONEQFidelity Nasdaq Composite Index ETF
    Weight in the fund0.01%

14 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

198 Managers, Q2 2026$3.3B Value of their positions
  • Q3 2025: Managers 130
  • Q4 2025: Managers 134
  • Q1 2026: Managers 197
  • Q2 2026: Managers 198

Institutional investors by quarter

The fund managers holding ALMS, quarter by quarter, from Q2 2024 to Q2 2025, 5 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 9 quarters.

Q2 2026: 198 managers held 118M shares, worth $3.3B. During the quarter 30 opened a position, 29 closed one, 70 added and 61 trimmed.

The largest holders, Q2 2026

  • AyurMaya Capital Management
    In the quarter
  • BlackRock
    In the quarter+15%
  • FMR
    In the quarter+595%
  • Deep Track Capital
    In the quarter-6.3%
  • Samsara Biocapital
    In the quarter
  • Foresite Capital Management V
    In the quarter
  • Price T Rowe Associates
    In the quarter+58%
  • venBio Partners
    In the quarter
  • Foresite Capital Management VI
    In the quarter
  • Vanguard Capital Management
    In the quarter+4.5%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Alumis's filings show?

Who buys and sells is one part of Alumis's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ALMS's shareholders

Didn't find what you were looking for?

Ask us
Which well-known managers hold ALMS?

5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $25M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.